Change of Nominated Adviser and Broker

RNS Number : 3991D

Tissue Regenix Group PLC

29 April 2013

 



29 April 2013

Tissue Regenix plc ("TRX" or "the Company")

Change of Nominated Adviser and Broker

Tissue Regenix plc (AIM : TRX) announces the appointment of Jefferies International Limited as Nominated Adviser and Broker to the Company with immediate effect.

-ENDS-

Contacts:

Tissue Regenix plc

[phone]

Antony Odell

Ian Jefferson

Newgate Communications

[phone]

Alistair Kellie /Andrew Adie

Jefferies International

[phone]

Simon Hardy /Henry Elphick

About Tissue Regenix plc

TRX is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

www.tissueregenix.com

 

END

 

 

APPPGUBCCUPWGAQ